A. Saci

发表

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Jun Zhu, C. Cordon-Cardo, W. Oh, 2018, Nature Communications.

RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis

P. Kang, J. Molkentin, A. Saci, 2014, Science Signaling.

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

M. Galsky, P. Sharma, A. Patnaik, 2019, Journal of Clinical Oncology.

BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity.

J. Kinet, A. Scharenberg, D. Rawlings, 2003, Immunity.

Tyrosine phosphorylation and association of FcγRII and p72Syk are not limited to the FcγRII signalling pathway

A. Saci, F. Rendu, C. Bachelot-Loza, 2000 .

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

E. Plimack, M. Galsky, P. Sharma, 2017, The Lancet. Oncology.

Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at a high shear rate occurs independently of (cid:1) IIb (cid:2) 3 engagement

P. Legendre, D. Baruch, A. Saci, 2003 .

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

Platelet α IIb-β 3 integrin engagement induces the tyrosine phosphorylation of Cbl and its association with phosphoinositide 3-kinase and Syk

A. Saci, F. Rendu, C. Bachelot-Loza, 2022 .

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

D. Schadendorf, D. Jackson, P. Ascierto, 2021, Cancer Immunology Research.

Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at a high shear rate occurs independently of αIIbβ3 engagement

P. Legendre, D. Baruch, A. Saci, 2003 .

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

M. Galsky, P. Sharma, P. Szabo, 2020, Clinical Cancer Research.

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

M. Galsky, P. Sharma, J. Blando, 2020, Science Translational Medicine.

Polygenic in vivo validation of cancer mutations using transposons

Lia S. Campos, L. Chin, P. Futreal, 2014, Genome Biology.

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.

M. Galsky, P. Sharma, A. Patnaik, 2020, Cancer cell.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

Fc Receptor-mediated Platelet Activation Is Dependent on Phosphatidylinositol 3-Kinase Activation and Involves p120 cbl *

A. Saci, F. Rendu, C. Bachelot-Loza, 1999, The Journal of Biological Chemistry.

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer

Yonghong Xiao, Lynda Chin, Valsamo Anagnostou, 2009, Nature.

Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.

L. Cantley, A. Saci, C. Carpenter, 2011, Molecular cell.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Jun Zhu, E. Plimack, W. Oh, 2019, European urology.

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Jun Zhu, M. Galsky, P. Sharma, 2018 .

848PDImpact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study

Matthew D. Galsky, Alexandre Lambert, C. Horak, 2017 .

Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at a high shear rate occurs independently of alpha IIb beta 3 engagement.

P. Legendre, D. Baruch, A. Saci, 2003, Blood.

Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement.

Abdelhafid Saci, Wang-Qing Liu, Michel Vidal, 2002, The Biochemical journal.

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

D. Schadendorf, D. Jackson, P. Ascierto, 2019, Clinical Trials.

Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

E. Plimack, P. Sharma, M. Grimm, 2016 .

Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275

E. Plimack, M. Galsky, P. Sharma, 2018, Clinical Trials.

Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD

C. Drake, D. Shaffer, A. Saci, 2019, Annals of Oncology.

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

A. Saci, Xiaozhong Qian, R. Moss, 2019, Clinical pharmacology and therapeutics.

RhoA GTPase regulates B cell receptor signaling.

A. Saci, C. Carpenter, 2005, Molecular cell.

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511).

P. Ascierto, M. Smylie, I. Svane, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

G. Caponigro, Z. Cao, M. Pinzon-Ortiz, 2013 .

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

P. Ascierto, B. Mellado, P. Sharma, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer

L. Chin, A. Protopopov, Yonghong Xiao, 2009, Nature.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Jun Zhu, C. Cordon-Cardo, W. Oh, 2018, Nature Communications.